Myastenia Gravis ve Timus Cerrahisi
Özet
Myastenia Gravis (MG), nöromusküler kavşakta asetilkolin reseptörlerini hedef alan antikorlar nedeniyle çizgili kaslarda yorgunluk ve güçsüzlükle seyreden otoimmün bir hastalıktır. Hastalık oküler, bulber veya jeneralize semptomlarla ortaya çıkabilmekte, alevlenme ve remisyonlarla değişken bir klinik seyir izlemektedir. Tedavi algoritmasında öncelikle pridostigmin ve immünsüpresif ajanları içeren medikal tedavi uygulanır. Ancak medikal tedaviye rağmen remisyon sağlanamayan durumlarda veya timoma varlığında cerrahi tedavi (timektomi) en önemli seçenek haline gelmektedir. Ameliyatın amacı, ektopik odak bırakılmaksızın timus bezinin ve çevre yağlı dokuların komplet rezeksiyonu ile uzun süreli tam stabil remisyon elde etmektir. Geleneksel transsternal yaklaşım geniş bir eksplorasyon sunsa da yüksek morbidite riskine sahiptir. Son yıllarda gelişen Video Yardımlı Torakoskopik Cerrahi (VATS) ve Robot Yardımlı Torakoskopik Cerrahi (RATS) gibi minimal invaziv teknikler, operasyon süresini kısaltarak, postoperatif ağrıyı azaltmakta ve hastanede kalış süresini düşürmektedir. Bu nedenle minimal invaziv yaklaşımlar, uygun nontimomatöz veya küçük timomalı olgularda standart tedavi yöntemi olarak konvansiyonel yöntemlerin yerini almaktadır.
Myasthenia Gravis (MG) is an autoimmune disorder characterized by muscle fatigue and weakness, driven by antibodies targeting acetylcholine receptors at the neuromuscular junction. The disease presents with ocular, bulbar, or generalized symptoms and exhibits a fluctuating clinical course with alternations of exacerbations and remissions. The primary treatment algorithm relies on medical therapy, including pyridostigmine and immunosuppressive agents. However, when medical therapy fails to achieve remission or when a thymoma is detected, surgical intervention (thymectomy) becomes the most critical definitive treatment option. The ultimate goal of surgery is to achieve long-term stable remission through the complete resection of the thymus gland and surrounding adipose tissues without leaving any ectopic remnants. Although the traditional transsternal approach offers extensive surgical exposure, it carries higher morbidity and prolonged hospitalization rates. Recently developed minimally invasive techniques, such as Video-Assisted Thoracoscopic Surgery (VATS) and Robotic-Assisted Thoracoscopic Surgery (RATS), provide superior postoperative patient comfort, minimal pain, and significantly shorter hospital stays. Consequently, these minimally invasive strategies have become the standard management for eligible non-thymomatous or small thymoma cases, increasingly replacing conventional open surgery.
Referanslar
Guptill JT, Sanders DB, Evoli A. Anti‐MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40.
McGrogan A, Sneddon S, De Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171–83.
Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest [Internet]. 2006 Nov 1;116(11):2843–54.
Toker A. Myastenia Gravis ve Timus Rezeksiyonları. In: Yüksel M, Balcı A, editors. Göğüs Cerrahisi “kırmızı kitap.” 2015. p. 713–9.
Li F, Ismail M, Elsner A, Uluk D, Bauer G, Meisel A, et al. Surgical techniques for myasthenia gravis: robotic-assisted thoracoscopic surgery. Thorac Surg Clin. 2019;29(2):177–86.
Cemeron D, Wright MD, Douglas J, Mathisen MD. Mediastinal tumours: Diagnosis and treatment. World J Surg. 2001;24:204–9.
Raza A, Woo E. Video-assisted thoracoscopic surgery versus sternotomy in thymectomy for thymoma and myasthenia gravis. Ann Cardiothorac Surg. 2016;5(1):33.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–22.
Mehdikhanova L. Asetilkolin Reseptör Antikoru Pozitif Myastenia Gravis Hastalarının Timektomi Materyallerinde Th17 Hücre İnfiltrasyonunun Değerlendirilmesi. 2014;
Katirji B, Kaminski HJ, Ruff RL. Neuromuscular disorders in clinical practice. Springer Science & Business Media; 2013.
Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014;175(3):408–18.
Deymeer F, Gungor-Tuncer O, Yılmaz V, Parman Y, Serdaroglu P, Ozdemir C, et al. Clinical comparison of anti-MuSK-vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007;68(8):609–11.
Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis. 2011;2011.
Maggi L, Andreetta F, Antozzi C, Baggi F, Bernasconi P, Cavalcante P, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol. 2008;201:237–44.
Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, et al. Titin antibodies in “seronegative” myasthenia gravis—a new role for an old antigen. J Neuroimmunol. 2016;292:108–15.
Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48(5):1253–60.
Mehrizi M, Pascuzzi RM. Complications of radiologic contrast in patients with myasthenia gravis. Muscle Nerve. 2014;50(3):443–4.
Melek H, Gebitekin C. Myastenia Graviste Timektomi Medikal Tedaviye Kıyasla Faydalı mıdır? In: Dural K, Özkan B, Özpolat B, editors. Timus Hastalıkları ve Tedavisi. Nobel tıp Kitabevi; 2019. p. 82–91.
Filosso PL, Ruffini E, Lausi PO, Lyberis P, Costardi L, Olivetti S, et al. Minimally-invasive surgery for non-thymomatous myasthenia gravis. 2018;
Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7–15.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–25.
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–22.
Mineo TC, Ambrogi V. Surgical techniques for myasthenia gravis: video-assisted thoracic surgery. Thorac Surg Clin. 2019;29(2):165–75.
Toker A, Sonett J, Zielinski M, Rea F, Tomulescu V, Detterbeck FC. Standard terms, definitions, and policies for minimally invasive resection of thymoma. J Thorac Oncol. 2011;6(7):S1739–42.
Renaud S, Santelmo N, Renaud M, Fleury M-C, De Seze J, Tranchant C, et al. Robotic-assisted thymectomy with Da Vinci II versus sternotomy in the surgical treatment of non-thymomatous myasthenia gravis: early results. Rev Neurol (Paris). 2013;169(1):30–6.
Wang G-W, Tao T, Li C-K, Li Q-C, Duan G-X, Sang H-W, et al. Comparison between thoracoscopic and open approaches in thymoma resection. J Thorac Dis. 2019;11(10):4159.
Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M, et al. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg. 1996;62(3):853–9.
Sonett JR. Thymectomy for myasthenia gravis: optimal approach. In: Difficult Decisions in Thoracic Surgery. Springer; 2007. p. 469–73.
